Vestal Point Capital, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001974915
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 76 positions · Total reported value $2.94B · Top-10 concentration 50.2% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 64.6% · 14 new · 20 cut · 19 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2025 13F filing, Vestal Point Capital, LP disclosed 76 equity positions with a combined reported value of $2.94B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 50.2% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were ABVX ($256.22M), QQQ ($215.01M), ACLX ($190.71M). By sector, the heaviest allocations are Health Care 75.5%, Other 24.5%. Versus the prior quarter, allocation shifted toward Other (+4.5pp) and away from Industrials (-2.0pp), Health Care (-2.5pp).
Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 50% of names.
The largest new positions opened in Q4 2025 were QQQ ($215.01M), TERN ($181.80M), MRK ($81.58M).
Of the 19 positions fully exited versus the prior quarter, the largest were FOLD ($76.83M), IONS ($70.33M), BDX ($60.83M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
Fully Exited (vs previous quarter)
- FOLD AMICUS THERAPEUTIC · prev qtr: $76.83M
- IONS IONIS PHARMACEUTICALS INC · prev qtr: $70.33M
- BDX BECTON DICKINSON & CO · prev qtr: $60.83M
- DNTH DIANTHUS THERAPEUTICS INC · prev qtr: $46.43M
- CYTK CYTOKINETICS INC · prev qtr: $39.85M
- BIIB BIOGEN INC · prev qtr: $38.52M
- CDTX CIDARA THERAPEUTICS INC COM NEW · prev qtr: $38.30M
- ATXS ASTRIA THERAPEUTICS INC · prev qtr: $36.08M
Insider Transactions (Form 4)
Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-127682 (status: Approved), registered 2023-04-14
- Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: vestalpoint.com
Portfolio Structure
- 63 positions · $3.87B reported value (Q3 2026)
- Top 10 holdings = 67.3% of reported value
- Largest position: ABVX (ABIVAX SA) at 10.1%
- Average position size: $61.44M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.90M | $256.22M | 8.71% | Add | |
| 2 |
|
350.00K | $215.01M | 7.31% | New | |
| 3 |
|
2.92M | $190.71M | 6.48% | Add | |
| 4 |
|
4.50M | $181.80M | 6.18% | New | |
| 5 |
|
3.00M | $178.29M | 6.06% | Add | |
| 6 |
|
1.27M | $111.32M | 3.79% | Add | |
| 7 |
|
4.69M | $88.97M | 3.02% | Add | |
| 8 |
|
1.10M | $87.09M | 2.96% | Hold | |
| 9 |
|
1.27M | $84.62M | 2.88% | Add | |
| 10 |
|
775.00K | $81.58M | 2.77% | New | |
| 11 |
|
13.75M | $75.62M | 2.57% | Add | |
| 12 |
|
600.00K | $75.17M | 2.56% | Add | |
| 13 |
|
6.12M | $64.31M | 2.19% | Reduce | |
| 14 |
|
2.42M | $63.75M | 2.17% | Hold | |
| 15 |
|
3.58M | $60.17M | 2.05% | Reduce | |
| 16 |
|
900.00K | $59.75M | 2.03% | New | |
| 17 |
|
3.83M | $58.98M | 2.00% | Add | |
| 18 |
|
735.00K | $58.37M | 1.98% | Add | |
| 19 |
|
290.00K | $49.30M | 1.68% | Reduce | |
| 20 |
|
5.20M | $48.46M | 1.65% | Add | |
| 21 |
|
4.47M | $44.44M | 1.51% | Add | |
| 22 |
|
2.48M | $44.23M | 1.50% | Add | |
| 23 |
|
550.00K | $41.51M | 1.41% | Add | |
| 24 |
|
1.65M | $41.25M | 1.40% | New | |
| 25 |
|
210.00K | $38.35M | 1.30% | Add | |
| 26 |
|
175.00K | $37.32M | 1.27% | Reduce | |
| 27 |
|
1.11M | $33.68M | 1.15% | Add | |
| 28 |
|
5.82M | $32.80M | 1.11% | Add | |
| 29 |
|
1.17M | $31.64M | 1.08% | Reduce | |
| 30 |
|
700.00K | $30.84M | 1.05% | Reduce | |
| 31 |
|
1.89M | $30.52M | 1.04% | Add | |
| 32 |
|
550.00K | $27.85M | 0.95% | Reduce | |
| 33 |
|
600.00K | $26.89M | 0.91% | Reduce | |
| 34 |
|
360.00K | $23.96M | 0.81% | Add | |
| 35 |
|
295.00K | $23.50M | 0.80% | Reduce | |
| 36 |
|
865.00K | $22.78M | 0.77% | Reduce | |
| 37 |
|
585.00K | $20.31M | 0.69% | New | |
| 38 |
|
720.00K | $19.55M | 0.67% | New | |
| 39 |
|
600.00K | $18.28M | 0.62% | Hold | |
| 40 |
|
1.50M | $17.79M | 0.60% | New | |
| 41 |
|
2.25M | $17.55M | 0.60% | New | |
| 42 |
|
50.00K | $15.55M | 0.53% | New | |
| 43 |
|
11.32M | $14.94M | 0.51% | Reduce | |
| 44 |
|
83.00K | $13.60M | 0.46% | Reduce | |
| 45 |
|
150.00K | $13.49M | 0.46% | New | |
| 46 |
|
250.00K | $13.48M | 0.46% | New | |
| 47 |
|
775.00K | $12.15M | 0.41% | Reduce | |
| 48 |
|
950.00K | $10.74M | 0.36% | New | |
| 49 |
|
1.61M | $9.68M | 0.33% | Reduce | |
| 50 |
|
1.05M | $9.53M | 0.32% | Add | |
FAQ
What did Vestal Point Capital, LP buy in 2025-Q4?
In its 2025-Q4 13F filing, Vestal Point Capital, LP reported 76 equity positions worth $2.94B in aggregate; its largest disclosed positions were ABVX ($256.22M), QQQ ($215.01M), ACLX ($190.71M).
How large is Vestal Point Capital, LP's portfolio?
Vestal Point Capital, LP reported $2.94B of long equity holdings across 76 positions as of 2025-Q4. Top-10 holdings account for 50.2% of reported value.
What is Vestal Point Capital, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.